Webinar recording: Reflections on a new era of managing NVAF patients during the COVID-19 crisis

Chaired by Professor Martin Cowie, Professor of Cardiology, Imperial College London (Royal Brompton Hospital), This webinar provides an update around the management of stroke/ systemic embolism (SE) prevention in atrial fibrillation (SPAF) during the COVID-19 pandemic and associated restrictions across the UK, reviewing how non-valvular atrial fibrillation (NVAF) patients have been managed over recent weeks and the impact of the pandemic on anticoagulation prescribing and monitoring.

Dr Jim Moore, GPSI Cardiology, Gloucestershire and President of Primary Care Cardiovascular Society discusses the recent guidance and the impact on managing NVAF patients during the pandemic, and reflects on how practice has changed, what lessons can be learnt, and what this means for the future of SPAF management.

This webinar was recorded in June 2020. This was a promotional webinar intended for UK Healthcare Professionals that was organised and fully funded by Bayer plc

We are regularly updating our website with new resources to support you and your patients. Please click here to subscribe to receive electronic communications about Bayer’s products, services and events.

To access the latest version of the Xarelto 2.5mg, 10mg and 15/20 mg Summary of Product Characteristics (SmPC) as well as Xarelto Patient Information Leaflet (PIL), please click on the following link eMC Widget

Reporting adverse events and quality complaints

This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.

If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 0118 206 3500 or Email: pvuk@bayer.com

Further information is available on the "contact" tab at www.bayer.co.uk.